|
1.
|
|
13 p, 266.5 KB |
Poorer quality of life and treatment satisfaction is associated with diabetic retinopathy in patients with type 1 diabetes without other advanced late complications
/
Granado-Casas, Minerva (Institut d'Investigació Biomèdica Sant Pau) ;
Castelblanco, Esmeralda (Institut d'Investigació Biomèdica Sant Pau) ;
Ramírez-Morros, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martín, Mariona (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Alcubierre, N. (Universitat de Lleida) ;
Martínez-Alonso, M. (Institut de Recerca Biomèdica de Lleida) ;
Valldeperas, Xavier (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Traveset, A. (Hospital Universitari Arnau de Vilanova) ;
Rubinat, Esther (Universitat de Lleida) ;
Lucas-Martin, Ana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Hernández, Marta (Hospital Universitari Arnau de Vilanova) ;
Alonso, N. (Instituto de Salud Carlos III) ;
Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Diabetic retinopathy (DR) may potentially cause vision loss and affect the patient's quality of life (QoL) and treatment satisfaction (TS). Using specific tools, we aimed to assess the impact of DR and clinical factors on the QoL and TS in patients with type 1 diabetes. [...]
2019 -  10.3390/jcm8030377
Journal of clinical medicine, Vol. 8 Núm. 3 (march 2019) , p. 377
|
|
|
2.
|
|
9 p, 213.6 KB |
Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations
/
Bancroft, E.K. (Institute of Cancer Research) ;
Saya, S. (Institute of Cancer Research) ;
Page, E.C. (Institute of Cancer Research) ;
Myhill, K. (Institute of Cancer Research) ;
Thomas, S. (Institute of Cancer Research) ;
Pope, J. (Institute of Cancer Research) ;
Chamberlain, A. (Institute of Cancer Research) ;
Hart, R. (Birmingham Women's Hospital) ;
Glover, W. (Birmingham Women's Hospital) ;
Cook, J. (Sheffield Children's Hospital (Sheffield, Regne Unit)) ;
Rosario, D.J. (Royal Hallamshire Hospital) ;
Helfand, B.T. (NorthShore University HealthSystem) ;
Hutten Selkirk, C. (NorthShore University HealthSystem) ;
Davidson, R. (Queen Elizabeth University Hospital) ;
Longmuir, M. (Queen Elizabeth University Hospital) ;
Eccles, D.M. (University of Southampton) ;
Gadea, Neus (Hospital Universitari Vall d'Hebron) ;
Brewer, C. (Royal Devon and Exeter Hospital) ;
Barwell, J. (University Hospitals Leicester) ;
Salinas, Monica (Hospital Universitari de Bellvitge) ;
Greenhalgh, L. (Liverpool Women's Hospital) ;
Tischkowitz, M. (University of Cambridge) ;
Henderson, A. (Newcastle upon Tyne Hospitals) ;
Evans, D.G. (Central Manchester University Hospitals NHS Foundation Trust) ;
Buys, S.S. (University of Utah Health) ;
Eeles, R.A. (Institute of Cancer Research) ;
Aaronson, N.K. (Netherlands Cancer Institute) ;
Capellá, Gabriel (Hospital Universitari de Bellvitge) ;
Ramon y Cajal, Teresa (Institut d'Investigació Biomèdica Sant Pau) ;
Mora Brugués, Josefina (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Esquena, Salvador (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Balmaña Gelpí, Judith (Hospital Universitari Vall d'Hebron) ;
Morote Robles, Juan (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi-national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic germline mutation in the BRCA1 or BRCA2 genes. [...]
2019 - 10.1111/bju.14412
BJU International, Vol. 123 Núm. 2 (february 2019) , p. 284-292
|
|
|
3.
|
|
10 p, 768.8 KB |
BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis : the prospective MABOMET GEICAM study
/
Barnadas i Molins, Agustí (Institut d'Investigació Biomèdica Sant Pau) ;
Muñoz, M. (Hospital Clínic i Provincial de Barcelona) ;
Margelí, M. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Chacón, J.I. (Hospital Virgen de la Salud) ;
Cassinello, J. (Hospital General de Guadalajara) ;
Antolin, S. (Complejo Hospitalario U. A Coruña) ;
Adrover, E. (Complejo Hospitalario Universitario de Albacete) ;
Ramos, M. (Centro Oncológico de Galicia) ;
Carrasco, E. (GEICAM (Spanish Breast Cancer Group)) ;
Jimeno, M.A. (GEICAM (Spanish Breast Cancer Group)) ;
Ojeda, B. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
González, X. (Hospital General de Catalunya) ;
González, S. (Hospital Mutua de Terrassa. Barcelona) ;
Constenla, M. (Complejo Hospitalario De Pontevedra) ;
Florián, J. (Hospital Comarcal de Barbastro) ;
Miguel, A. (Hospital Althaia Manresa) ;
Llombart, A. (Hospital Arnau de Vilanova) ;
Lluch, A. (Hospital Clínic Universitari (València)) ;
Ruiz-Borrego, M. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Colomer, R. (Hospital Universitario La Princesa) ;
Del Barco, S. (Hospital Universitari de Girona Doctor Josep Trueta) ;
Universitat Autònoma de Barcelona
Bone metastasis (BM) is the most common site of disease in metastatic breast cancer (MBC) patients. BM impacts health-related quality of life (HRQoL). We tested prospectively the psychometric properties of the Bone Metastasis Quality of Life (BOMET-QoL-10) measure on MBC patients with BM. [...]
2019 - 10.1186/s41687-019-0161-y
Journal of Patient-Reported Outcomes, Vol. 3 Núm. 1 (january 2019) , p. 72
|
|
|
4.
|
|
7 p, 769.8 KB |
An analysis of patient-reported outcomes in ixora-s : Comparing ixekizumab and ustekinumab over 52 weeks in moderate-to-severe psoriasis
/
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Lomaga, M. (DermEdge Research and Probity Medical Research) ;
Hollister, K. (Eli Lilly and Company) ;
Dutronc, Y. (Eli Lilly and Company) ;
Berggren, L. (HaaPACS GmbH) ;
Van De Kerkhof, P. (Radboud University Nijmegen Medical Centre) ;
Universitat Autònoma de Barcelona
Patient-reported outcomes are valuable for assessing new psoriasis therapies. This study investigated patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with ixekizumab or ustekinumab, dosed according to their respective labels, for 52 weeks (IXORA-S-NCT02561806). [...]
2020 - 10.2340/00015555-3700
Acta dermato-venereologica, Vol. 100 Núm. 19 (2020) , p. 1-7
|
|
|
5.
|
|
16 p, 329.8 KB |
Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective : An Observational Cross-Sectional Study
/
Meca-Lallana, José E. (Hospital Universitario Virgen de la Arrixaca. Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca. Unidad de Neuroinmunología Clínica y Esclerosis Múltiple CSUR. Servicio de Neurología) ;
Gómez-Ballesteros, Rocío (Medical Department. Roche Farma) ;
Pérez-Miralles, Francisco (Hospital Universitari i Politècnic La Fe. Unidad de Neuroinmunología. Servicio de Neurología) ;
Forero, Lucía (Hospital Universitario Puerta del Mar. Servicio de Neurología) ;
Sepúlveda, María (Hospital Clínic i Provincial de Barcelona) ;
Calles, Carmen (Hospital Universitario Son Espases. Servicio de Neurología) ;
Martínez-Ginés, María L. (Hospital General Universitario Gregorio Marañón) ;
González-Suárez, Inés (Hospital Universitario Álvaro Cunqueiro. Servicio de Neurología) ;
Boyero, Sabas (Hospital de Cruces (Barakaldo). Servicio de Neurología) ;
Romero-Pinel, Lucía (Hospital Universitari de Bellvitge) ;
Sempere, Ángel P. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Meca-Lallana, V. (Department of Neurology. Hospital Universitario La Princesa) ;
Querol, Luis (Institut d'Investigació Biomèdica Sant Pau) ;
Costa-Frossard, Lucienne (Hospital Universitario Ramón y Cajal (Madrid)) ;
Prefasi, Daniel (Medical Department. Roche Farma) ;
Maurino, Jorge (Medical Department. Roche Farma)
Introduction: Neuromyelitis optica spectrum disorder (NMOSD) is associated with a reduced health-related quality of life (HRQoL). The purpose of this study was to describe the impact of NMOSD on HRQoL from the patients' perspective and its relationship with other disease factors. [...]
2022 - 10.1007/s40120-022-00356-6
Neurology and Therapy, Vol. 11 Núm. 3 (september 2022) , p. 1101-1116
|
|
|
6.
|
|
11 p, 1.2 MB |
Quality of life and cost-effectiveness analysis of topical tranexamic acid and fibrin glue in femur fracture surgery
/
Merchán Galvis, Ángela María (Institut d'Investigació Biomèdica Sant Pau) ;
Posso, M. (Institut Hospital del Mar d'Investigacions Mèdiques. Department of Epidemiology and Evaluation) ;
Canovas, E. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Jordán, M. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Aguilera, Xavier (Institut d'Investigació Biomèdica Sant Pau) ;
Martinez-Zapata, Maria José (Institut d'Investigació Biomèdica Sant Pau)
Background: We assessed quality of life (QoL) of patients undergoing surgery for proximal femur fracture and performed a cost-effectiveness analysis of haemostatic drugs for reducing postoperative bleeding. [...]
2022 - 10.1186/s12891-022-05775-y
BMC musculoskeletal disorders, Vol. 23 Núm. 1 (december 2022) , p. 827
|
|
|
7.
|
|
10 p, 1.7 MB |
Assessing the Relationship of Patient Reported Outcome Measures With Functional Status in Dysferlinopathy : A Rasch Analysis Approach
/
Mayhew, Anna G. (The John Walton Muscular Dystrophy Research Centre. Translational and Clinical Research Institute. Newcastle University and Newcastle Hospitals NHS Foundation Trust) ;
James, Meredith K. (The John Walton Muscular Dystrophy Research Centre. Translational and Clinical Research Institute. Newcastle University and Newcastle Hospitals NHS Foundation Trust) ;
Moore, Ursula (The John Walton Muscular Dystrophy Research Centre. Translational and Clinical Research Institute. Newcastle University and Newcastle Hospitals NHS Foundation Trust) ;
Sutherland, Helen (The John Walton Muscular Dystrophy Research Centre. Translational and Clinical Research Institute. Newcastle University and Newcastle Hospitals NHS Foundation Trust) ;
Jacobs, Marni (Pediatrics. Epidemiology and Biostatistics. George Washington University) ;
Feng, Jia (Center for Translational Science. Division of Biostatistics and Study Methodology. Children's National Health System) ;
Lowes, Linda Pax (The Abigail Wexner Research Institute at Nationwide Children's Hospital) ;
Alfano, Lindsay N. (The Abigail Wexner Research Institute at Nationwide Children's Hospital) ;
Muni Lofra, Robert (The John Walton Muscular Dystrophy Research Centre. Translational and Clinical Research Institute. Newcastle University and Newcastle Hospitals NHS Foundation Trust) ;
Rufibach, Laura E. (The Jain Foundation) ;
Rose, Kristy (The Children's Hospital at Westmead. The University of Sydney) ;
Duong, Tina (Lucile Salter Packard Children's Hospital at Stanford. Neurology) ;
Bello, L. (Department of Neuroscience. University of Padova) ;
Pedrosa-Hernández, Irene (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Holsten, S. (Neuroscience Institute. Carolinas Neuromuscular/ALS-MDA Center. Carolinas HealthCare System) ;
Sakamoto, C. (Department of Physical Rehabilitation. National Center Hospital. National Center of Neurology and Psychiatry Tokyo) ;
Canal, Aurélie (Institut de Myologie. AP-HP. GH Pitié-Salpêtrière) ;
Sánchez-Aguilera Práxedes, N. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Thiele, S. (Department of Neurology. Friedrich-Baur-Institute. Ludwig-Maximilians-University of Munich) ;
Siener, C. (Department of Neurology. Washington University School of Medicine) ;
Vandevelde, B. (Service des Maladies Neuromusculaire et de la SLA. Hôpital de La Timone) ;
DeWolf, B. (Cooperative International Neuromuscular Research Group. Children's National Health System) ;
Maron, E. (ELAN-PHYSIO. Praxis für Physiotherapie Maron) ;
Gordish-Dressman, H. (Pediatrics. Epidemiology and Biostatistics. George Washington University) ;
Hilsden, H. (The John Walton Muscular Dystrophy Research Centre. Translational and Clinical Research Institute. Newcastle University and Newcastle Hospitals NHS Foundation Trust) ;
Guglieri, M. (The John Walton Muscular Dystrophy Research Centre. Translational and Clinical Research Institute. Newcastle University and Newcastle Hospitals NHS Foundation Trust) ;
Hogrel, J.Y. (Institut de Myologie. AP-HP. GH Pitié-Salpêtrière) ;
Blamire, A.M. (Magnetic Resonance Centre. Institute for Cellular Medicine. Newcastle University) ;
Carlier, P.G. (AIM CEA NMR Laboratory. Institute of Myology. Pitié-Salpêtrière University Hospital) ;
Spuler, S. (Charite Muscle Research Unit. Experimental and Clinical Research Center. A Joint Cooperation of the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine) ;
Day, J.W. (Department of Neurology and Neurological Sciences. Stanford University School of Medicine) ;
Jones, K.J. (The Children's Hospital at Westmead. The University of Sydney) ;
Bharucha-Goebel, D.X. (National Institutes of Health (Bethesda, Estats Units d'Amèrica)) ;
Salort-Campana, E. (Service des Maladies Neuromusculaire et de la SLA. Hôpital de La Timone) ;
Pestronk, A. (Department of Neurology. Washington University School of Medicine) ;
Walter, M.C. (Department of Neurology. Friedrich-Baur-Institute. Ludwig-Maximilians-University of Munich) ;
Paradas, C. (Instituto de Biomedicina de Sevilla) ;
Stojkovic, T. (Institut de Myologie. AP-HP. GH Pitié-Salpêtrière) ;
Mori-Yoshimura, M. (Department of Neurology. National Center Hospital. National Center of Neurology and Psychiatry Tokyo) ;
Bravver, E. (Neuroscience Institute. Carolinas Neuromuscular/ALS-MDA Center. Carolinas HealthCare System) ;
Diaz-Manera, Jordi (Institut d'Investigació Biomèdica Sant Pau) ;
Pegoraro, E. (Department of Neuroscience. University of Padova) ;
Mendell, J. R. (The Abigail Wexner Research Institute at Nationwide Children's Hospital) ;
Jain COS Consortium, None (The Abigail Wexner Research Institute at Nationwide Children's Hospital) ;
Straub, V. (The John Walton Muscular Dystrophy Research Centre. Translational and Clinical Research Institute. Newcastle University and Newcastle Hospitals NHS Foundation Trust)
Dysferlinopathy is a muscular dystrophy with a highly variable functional disease progression in which the relationship of function to some patient reported outcome measures (PROMs) has not been previously reported. [...]
2022 - 10.3389/fneur.2022.828525
Frontiers in neurology, Vol. 13 (october 2022) , p. 828525
|
|
|
8.
|
|
11 p, 349.0 KB |
Chronic nodular prurigo : clinical profile and burden. A European cross-sectional study
/
Pereira, Manuel Pedro (University Hospital of Münster (Alemanya)) ;
Hoffmann, V. (University Hospital of Münster (Alemanya)) ;
Weisshaar, E. (University of Heidelberg) ;
Wallengren, J. (Dermatology and Venereology and Skane University Hospital) ;
Halvorsen, J.A. (Oslo University Hospital (Oslo, Noruega)) ;
Garcovich, S. (Università Cattolica del Sacro Cuore) ;
Misery, L. (University Hospital of Brest) ;
Brenaut, Emilie (University Hospital of Brest) ;
Savk, E. (Aydin Adnan Menderes University) ;
Potekaev, N. (Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology) ;
Lvov, A. (Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology) ;
Bobko, S. (Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology) ;
Szepietowski, J.C. (Wroclaw Medical University) ;
Reich, A. (University of Rzeszów) ;
Bozek, A. (University of Information Technology and Management) ;
Legat, F.J. (Medical University of Graz) ;
Metz, M. (Charité - Universitätsmedizin Berlin) ;
Streit, M. (Kantonsspital Aarau) ;
Serra-Baldrich, E (Institut d'Investigació Biomèdica Sant Pau) ;
Gonçalo, M. (University of Coimbra) ;
Storck, M. (University of Münster) ;
Greiwe, I. (University Hospital of Münster (Alemanya)) ;
Nau, T. (University Hospital of Münster (Alemanya)) ;
Steinke, S. (University Hospital of Münster (Alemanya)) ;
Dugas, M. (University of Münster) ;
Ständer, S. (University Hospital of Münster (Alemanya)) ;
Zeidler, C. (University Hospital of Münster (Alemanya)) ;
Dalgard, F. ;
Elberling, J. ;
Forner, C. ;
Leslie, T. ;
Riepe, C. ;
Schneider, G. ;
Ständer, H. ;
Universitat Autònoma de Barcelona
Chronic nodular prurigo (CNPG) is a condition characterized by chronic itch, a prolonged scratching behaviour and the presence of pruriginous nodules. A comprehensive understanding of this condition, especially regarding its clinical characteristics and impact on quality of life is still lacking. [...]
2020 - 10.1111/jdv.16309
Journal of the European Academy of Dermatology and Venereology, Vol. 34 Núm. 10 (january 2020) , p. 2373-2383
|
|
|
9.
|
|
15 p, 1.6 MB |
Psychiatric and neurocognitive consequences of endogenous hypercortisolism
/
Piasecka, M. (Sahlgrenska University Hospital (Suècia)) ;
Papakokkinou, E. (Sahlgrenska University Hospital (Suècia)) ;
Valassi, E. (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Santos, Alicia (Institut d'Investigació Biomèdica Sant Pau) ;
Webb, Susan 1952- (Institut d'Investigació Biomèdica Sant Pau) ;
de Vries, F. (Leiden University Medical Center) ;
Pereira, A.M. (Leiden University Medical Center) ;
Ragnarsson, O. (Sahlgrenska University Hospital (Suècia)) ;
Universitat Autònoma de Barcelona
Psychiatric and neurocognitive symptoms due to hypercortisolism were already described by Harvey Cushing in his original paper on patients with Cushing's syndrome (CS). Nowadays, it is well known that psychiatric and cognitive complaints are two of the most common, and most distressing, symptoms in patients with CS. [...]
2020 - 10.1111/joim.13056
Journal of Internal Medicine, Vol. 288 Núm. 2 (january 2020) , p. 168-182
|
|
|
10.
|
|
11 p, 1.9 MB |
Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice
/
Laquente, B. (Hospital Duran i Reynals (Hospitalet del Llobregat)) ;
Macarulla Mercadé, Teresa (Vall d'Hebron Institut d'Oncologia) ;
Bugés, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martín, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
García, C. (Complejo Hospitalario de Burgos) ;
Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Merino, S. (Hospital Sant Joan de Reus) ;
Visa, Laura (Hospital del Mar (Barcelona, Catalunya)) ;
Martín, T. (Hospital Universitario de Salamanca) ;
Pedraza, M. (Complejo Asistencial Universitario de León) ;
Carnero, B. (Hospital El Bierzo) ;
Guardeño, R. (Institut Català d'Oncologia) ;
Verdaguer, Helena (Vall d'Hebron Institut d'Oncologia) ;
Mut, A. (Celgene S.L.U) ;
Vilanova, D. (Celgene S.L.U) ;
García, A. (Institut Català d'Oncologia) ;
Universitat Autònoma de Barcelona
Despite advances in surgery, radiotherapy, and chemotherapy, pancreatic adenocarcinoma often progresses rapidly and causes death. The physical decline of these patients is expected to impact their quality of life (QoL). [...]
2020 - 10.1186/s12904-020-00610-4
BMC Palliative Care, Vol. 19 Núm. 1 (october 2020) , p. 610
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
